Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study

BACKGROUND: Raltitrexed plus S-1 (RS) and regorafenib both showed considerable efficacy for metastatic colorectal cancer (mCRC) patients. This study aims to compare the effectiveness and safety of two different regimens in patients with refractory mCRC. METHODS: This retrospective cohort study inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yu-Wen, Wang, Jia-Ling, Li, Qing-Fang, He, Yuan-Lin, Li, Lin-Juan, Liu, Rui-Zhi, Chen, Ye, Zhang, Shuang, Qiu, Meng, Liu, Ji-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121501/
https://www.ncbi.nlm.nih.gov/pubmed/35601804
http://dx.doi.org/10.1177/17562848221098246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121501/
https://www.ncbi.nlm.nih.gov/pubmed/35601804
http://dx.doi.org/10.1177/17562848221098246

Ejemplares similares